##StemCell derived ##ChimericAntigenReceptor (CAR) ##NaturalKillerCells show potential for treating ##BCellLymphomas and could make future cellular ##immunotherapies less expensive and more accessible to patients.
##Phase1Trial
##Phase1Trial
New cellular immunotherapy approach shows promise for B-cell lymphoma – BioNews Central
Stem-cell-derived chimeric antigen receptor (CAR) natural killer cells show potential for treating B-cell lymphomas and could make future cellular immunotherapies less expensive and more accessible to patients. ...
sbee.link
January 15, 2025 at 1:02 PM
##StemCell derived ##ChimericAntigenReceptor (CAR) ##NaturalKillerCells show potential for treating ##BCellLymphomas and could make future cellular ##immunotherapies less expensive and more accessible to patients.
##Phase1Trial
##Phase1Trial
Our latest learning article, supported by BeOne Medicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice
#ukpharmacy #cancer #bcelllymphomas
#ukpharmacy #cancer #bcelllymphomas
Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists
Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…
buff.ly
October 3, 2025 at 7:30 AM
Our latest learning article, supported by BeOne Medicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice
#ukpharmacy #cancer #bcelllymphomas
#ukpharmacy #cancer #bcelllymphomas